Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib, Dasatinib, Prednisone, and Blinatumomab in Newly Diagnosed Ph+ ALL
NCT06773936Phase 2Enrolling by invitation
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 2026
- Primary completion
- May 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asciminib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by SWOG Cancer Research Network. Primary endpoint: Major molecular remission by polymerase chain reaction for BCR-ABL at 100 days. Started Apr 2026; status: enrolling by invitation.
02
Drugs
asciminib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT06773936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773936.